the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease.

the Role of plin5 in the Development of a Sequence Polymorphism in Patatin-like Phospholipid Domain Containing Protein 3 Polymorphism-associated Nonalcoholic Fatty Liver Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04104282

Enrollment

240

Registered

2019-09-26

Start date

2016-12-01

Completion date

2025-12-27

Last updated

2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic Fatty Liver Disease

Keywords

Nonalcoholic fatty liver disease, Lipid droplets, Plin5

Brief summary

To further clarify the role of sequence polymorphism in patatin-like phospholipid domain containing protein 3 in the development of nonalcoholic fatty liver disease.

Detailed description

A sequence polymorphism in patatin-like phospholipid domain containing protein 3 is significantly associated with nonalcoholic fatty liver disease, but its mechanism underlying this association remains obscure. We introduce the human samples of liver to clarify the relationship between the expression of plin5 and the development of sequence polymorphism in patatin-like phospholipid domain containing protein 3 variant-associated nonalcoholic fatty liver disease, analyze the lipid metabolism and lipotoxicity of hepatocytes to elucidate the mechanisms of plin5 in the development of sequence polymorphism in patatin-like phospholipid domain containing protein 3 variant-associated nonalcoholic fatty liver disease. Our study will contribute to the mechanism of nonalcoholic fatty liver disease, and its prevention and therapy.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

The diagnosis of simple fatty liver disease was confirmed by clinical presentation, ultrasound, and without long-term drinking history, viral hepatitis, medication history, obesity (BMI≥30), type 2 diabetes and other metabolic diseases.

Exclusion criteria

With long-term drinking history, viral hepatitis, medication history, obesity (BMI≥30), type 2 diabetes and other metabolic diseases.

Design outcomes

Primary

Measure	Time frame	Description
The severity of non-alcoholic fatty liver disease	3 months	Evaluating by ultrasound the severity of non-alcoholic fatty liver disease

Secondary

Measure	Time frame	Description
The expression of plin5	3 months	Evaluating by biochemical methods the expression of plin5 in patients liver tissue

Countries

China

Contacts

Primary ContactMing Yu, PhD, MD

huihui2807201830@163.com15209239680

Backup ContactHuihui Zhou, MD

huihui2807201830@126.com18066896622

Outcome results